Business Context and Reporting Period
Company: Damora Therapeutics, Inc. (formerly Galecto, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: A biopharmaceutical company developing therapies for hematological malignancies, specifically myeloproliferative neoplasms (MPNs) driven by mutant calreticulin (mutCALR). The company focuses on a portfolio of three product candidates: DMR-001 (Fc-null antibody), DMR-002 (afucosylated antibody), and DMR-003 (bi-specific T-cell engager).
Recent Corporate Actions: In November 2025, the company completed an asset acquisition of "Pre-Acquisition Damora" and a concurrent PIPE transaction. In February 2026, it completed a public offering and converted significant Series C Preferred Stock to Common Stock. In July 2026, the company redomesticated from Delaware to the Cayman Islands.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Three Months Ended June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(58,957) | $(5,970) | $(31,174) |
| Operating Expenses | $65,805 | $6,020 | $34,994 |
| Research & Development (R&D) | $49,317 | $2,143 | $25,540 |
| General & Administrative (G&A) | $16,488 | $3,877 | $9,454 |
| Cash and Cash Equivalents (End of Period) | $540,515 | $10,211 | $540,515 |
| Net Cash Used in Operating Activities | $(42,465) | $(4,676) | N/A |
| Net Cash Provided by Financing Activities | $325,426 | $0 | N/A |
| Accumulated Deficit | $(546,320) | $(283,494) | $(546,320) |
Material Changes vs. Prior Period
- Expense Surge: Total operating expenses increased by 993% to $65.8 million for the six months ended June 30, 2026, compared to $6.0 million in the prior year period. This is primarily due to the integration of the Pre-Acquisition Damora assets and accelerated development activities.
- R&D Drivers: R&D expenses rose to $49.3 million, driven by $17.8 million in reimbursable costs under the Paragon Option Agreement, $9.5 million in amortized costs for the Paramora warrant obligation, and $18.8 million in Chemistry, Manufacturing, and Control (CMC) activities.
- Liquidity Position: Cash and cash equivalents increased significantly from $257.6 million at year-end 2025 to $540.5 million at June 30, 2026. This increase was fueled by a February 2026 underwritten public offering (net proceeds ~$295.5 million) and an At-the-Market (ATM) offering (net proceeds ~$29.3 million).
- Capital Structure: Significant conversions occurred, including the automatic conversion of 42,005 shares of Series C Preferred Stock into 42,005,000 shares of Common Stock following stockholder approval in February 2026.
Guidance, Outlook, and Risks
- Development Timeline: The company has initiated the Phase 1/1b clinical trial for DMR-001. It plans to submit regulatory filings for DMR-002 in the second half of 2026 and for DMR-003 in 2027. Proof-of-concept readouts for DMR-001 are expected beginning mid-2027.
- Liquidity Outlook: Management believes existing cash resources of $540.5 million are sufficient to fund operations into the second half of 2029. However, the company expects to continue incurring losses and will require additional capital to complete development and commercialization.
- Key Risks:
- Development Risk: No products have been approved for commercial sale; success depends on clinical trial outcomes and regulatory approvals.
- Third-Party Reliance: Significant reliance on Paragon Therapeutics for research and development under the Paragon Option Agreement, including potential milestone payments up to $22.0 million per product.
- Regulatory/Geopolitical: Risks associated with the BIOSECURE Act regarding reliance on Chinese contract manufacturing organizations (e.g., WuXi Biologics) and potential tariffs on imported pharmaceuticals.
- Intellectual Property: The company does not currently own issued patents for its product candidates; rights are held by Paragon and subject to licensing.
Investor Verification Checklist
- Capital Runway: Verify the accuracy of the "second half of 2029" liquidity projection given the high burn rate ($42.5 million operating cash outflow in six months).
- Paragon Agreement Terms: Review the specific milestones and payment triggers under the Paragon Option Agreement, particularly the $22.0 million potential liability per product.
- Manufacturing Supply Chain: Assess the impact of the BIOSECURE Act and potential tariffs on the company's reliance on WuXi Biologics (Hong Kong) for clinical trial materials.
- Patent Status: Confirm the timeline for transferring patent prosecution control from Paragon to Damora and the status of pending applications for DMR-001, DMR-002, and DMR-003.
- Stock Dilution: Monitor the remaining capacity under the $150 million ATM facility and the conversion terms of the remaining Series B and Series C Preferred Stock.